

Pramipexole Reduces Phosphorylation of α -Synuclein at Serine-129

Kai-Yin Chau · J. Mark Cooper · Anthony Henry V. Schapira

Received: 27 February 2013 / Accepted: 6 May 2013 / Published online: 18 May 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract α -Synuclein is a central component of the pathogenesis of Parkinson's disease (PD). Phosphorylation at serine-129 represents an important post-translational modification and constitutes the major form of the protein in Lewy bodies. Several kinases have been implicated in the phosphorylation of α -synuclein. The targeting of kinase pathways as a potential to influence the pathogenesis of PD is an important focus of attention, given that mutations of specific kinases (LRRK2 and PINK1) are causes of familial PD. Pramipexole (PPX) is a dopamine agonist developed for the symptomatic relief of PD. Several in vitro and in vivo laboratory studies have demonstrated that PPX exerts neuroprotective properties in model systems of relevance to PD. The present study demonstrates that PPX inhibits the phosphorylation of α -synuclein and that this is independent of dopamine receptor activation. PPX blocks the increase in phosphorylated α -synuclein induced by inhibition of the ubiquitin proteasomal system. The phosphorylation of α -synuclein occurs in part at least through casein kinase 2, and PPX in turn reduces the phosphorylation of this enzyme, thereby inhibiting its activity. Thus, PPX decreases the phosphorylation of α -synuclein, and this mechanism may contribute to its protective properties in PD models.

Keywords Parkinson's disease · Neurodegeneration · Pramipexole · α -Synuclein · Phosphorylation · Neuroprotection · Dopamine agonists

Electronic supplementary material The online version of this article (doi:10.1007/s12031-013-0030-8) contains supplementary material, which is available to authorized users.

K.-Y. Chau · J. M. Cooper · A. H. V. Schapira (✉)
Department of Clinical Neurosciences, Institute of Neurology,
University College London, Rowland Hill Street,
London NW3 2PF, UK
e-mail: a.schapira@ucl.ac.uk

Introduction

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised in its early stages by the motor features of bradykinesia, rigidity and tremor, which in turn are related predominantly to dopamine cell loss in the substantia nigra pars compacta. This pathology, together with degeneration of other neurotransmitter systems, is also associated with non-motor symptoms that evolve with disease progression (Chaudhuri et al. 2006; Fox et al. 2008; Chaudhuri and Schapira 2009). Although dopamine replacement therapy can improve quality of life and life expectancy, a major unmet need in PD is the ability to slow or stop the progression of neurodegeneration (Olanow et al. 2008; Schapira et al. 2009).

The pathogenesis of PD is thought to involve a number of intersecting pathways that include mitochondrial dysfunction, oxidative stress, lysosomal abnormalities and protein aggregation (Schapira 2006). A substantial number of compounds have been proposed to have an effect of slowing PD degeneration by interfering with these pathways, based mainly on the results of laboratory studies (Schapira 2009a, b). Dopamine agonists and monoamine oxidase B inhibitors have demonstrated neuroprotective properties in a variety of in vitro and in vivo models of PD and are thought to exhibit antioxidant and anti-apoptotic properties (for reviews, see Schapira et al. 2009; Schapira 2009a).

The deposition of α -synuclein as the major constituent of Lewy bodies and the discovery that mutations and multiplications of the α -synuclein gene are causes of familial PD have focussed attention on this protein in the pathogenesis of PD (Fuchs et al. 2008; Ross et al. 2008). It is notable that the predominant form of α -synuclein in Lewy bodies is phosphorylated at its serine-129 residue (Fujiwara et al. 2002; Anderson et al. 2006), and this phosphorylation is increased in A53T α -synuclein expression (Wakamatsu et al. 2007). The kinase pathways that perform this phosphorylation have not

yet been fully identified and may involve multiple sequential stages. The phosphorylated form of α -synuclein can be toxic to dopaminergic cells and this is increased by oxidative stress and proteasomal inhibition (Chau et al. 2009). Post-translational modification in the form of phosphorylation appears to be of significance to a number of pathways involved in dopaminergic cell death (Dagda et al. 2009; Obeso et al. 2010; Schapira and Tolosa 2010; Sha et al. 2010).

Several studies have demonstrated that mitochondrial function may be influenced by α -synuclein (Devi et al. 2010; Nakamura et al. 2011), although the role that serine-129 phosphorylation may play in this has not been elucidated. The D2/D3 dopamine agonist pramipexole (PPX) has demonstrated that it is capable of reducing cell death in toxin models of dopamine loss *in vitro* and *in vivo* and that this may in part be through an action on mitochondria possibly at the level of the permeability transition pore (Schapira 2008). Our studies on PPX and its potential for neuroprotection led us to investigate the relationship between this compound and α -synuclein phosphorylation. We hypothesised that PPX may reduce phosphorylation at the serine-129 residue site of α -synuclein and that this contributes to the drug's protective role in PD models.

Materials and Methods

Cell Culture

A human dopaminergic cell line SH-SY5Y, stably overexpressing human wild-type α -synuclein tagged with haemagglutinin (HA) at its C terminus was cultured as previously described (Chau et al. 2009). Cell culture reagents were supplied by Life Technologies (Paisley, UK).

Treatments and Samples Collection

Cells were plated at subconfluent density, to which PPX and its enantiomer SND919CL2x (SND) (Boehringer Ingelheim GmbH, Ingelheim, Germany), dopamine receptors antagonist clozapine (Tocris, R&D Systems, Abingdon, UK) and epoxomicin (Calbiochem, San Diego CA, USA) were added. 5,6-Dichloro-1- β -D-ribofuranosylbenzimidazole (DRB) was obtained from Enzo Life Sciences (Exeter, UK), whereas 4,5,6,7-tetrabromo-2-azabenzimidazole (TBB) was obtained from Sigma-Aldrich (Dorset, UK). Where kinase activities were measured, okadaic acid (OKA; Calbiochem, San Diego CA, USA) was added to 1 μ g/ μ l 30 min before cells were harvested. Upon collecting the samples, cells were washed with phosphate-buffered saline (PBS) twice and lysed *in situ* in a buffer containing 1 % Triton X-100, 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM Na₃VO₄ and 50 μ M NaF. Cell lysates were collected and spun at 21,000 \times g at 4 °C for 10 min, and soluble materials were

retained for Western blot analysis. Bafilomycin A1 was obtained from Sigma-Aldrich (Dorset, UK).

Western Blot Analysis and Densitometry

Equal amounts of protein (as determined by bicinchoninic acid [BCA] assays; Pierce, Rockford, IL, USA) from the soluble materials were resolved under reducing conditions in NuPAGE 4–12 % polyacrylamide gels (Invitrogen, Carlsbad, CA, USA), using the MES buffer, and transferred onto Immobilon PVDF membrane (Millipore, Billerica, MA, USA). Antibodies detecting HA epitope (Covance, Princeton, NJ, USA), phospho-serine-129 (P-S129) of α -synuclein (Wako, Neuss, Germany), α -synuclein (clone LB509; Invitrogen, Carlsbad, CA, USA), β -actin (Abcam, Cambridge, UK), phospho-serine-209 (P-S209), pan-casein kinase 2- β (Abcam, Cambridge, UK) and ubiquitin (Abcam, Cambridge, UK) were used, and the secondary antibodies detecting mouse and rabbit IgG were supplied by Dako (Glostrup, Denmark). ECL reagent (GE Healthcare, Bucks, UK) was used to develop the immunostained blots, and signals were detected by ECL films (GE Healthcare, Bucks, UK). Images on X-ray films were scanned with a trans-illuminating light source and densities measured using the DigiDoc gel analysis software (Alpha Innotech, East Sussex, UK).

Measurements on Lactate Dehydrogenase Release

Cell death was quantified by lactate dehydrogenase (LDH) release as described in Chau et al. (2009) using the kit manufactured by Promega (Southampton, UK).

Quantification of α -Synuclein Oligomerisation

Total level of α -synuclein was measured using the enzyme-linked immunosorbent assay (ELISA) kit supplied by Life Technologies (Paisley, UK). α -Synuclein oligomers was quantified using the same ELISA kit, with the detection antibody replaced with the oligomer antibody clone A11 (Life Technologies, Paisley, UK). Data were expressed as immunoactivity of A11 relative to the antibody detecting the total level of α -synuclein.

Biochemical Kinase Profiling

In vitro inhibition of a kinase library by 10 μ M PPX was measured commercially by SelectScreen biochemical kinase profiling (Life Technologies, Paisley, UK).

Proteasomal Activity Measurements

Cells collected, after being washed with PBS twice, were frozen and thawed three times in 10 mM Tris-HCl pH 7.5.

Cell lysates were loaded onto a black 96-well plate and mixed with the respective fluorogenic substrate for PGP, chymotrypsin and trypsin-like activities (Calbiochem, San Diego CA, USA) at 80 μM final concentration. V_{max} was measured in a fluorescent plate reader with the chamber temperature set to 32 °C for 20 min at excitation and emission of 380 and 460 nm, respectively. V_{max} was corrected by protein concentration as determined by the BCA assays.

Statistical Analysis

Paired *t* tests were conducted where two groups were compared, and one-way analysis of variance (ANOVA) followed by Dunnett's post test was used for multiple comparisons to the control group. In both cases, $p < 0.05$ was deemed significant.

Results

Pramipexole Decreased the Constitutive Level and Formation Rate of α -Synuclein Phosphorylation at Serine-129

To establish marker measurements, levels of P-S129 and the total ectopic level of α -synuclein were measured by Western blot analysis on 1 % Triton cell lysates, using the antibodies specifically detecting P-S129 (as demonstrated in Fig. 1 in Chau et al. 2009 and Fig. S1) and HA, respectively. In our hands, the endogenous level of α -synuclein in SH-SY5Y cells is undetectable (Chau et al. 2009 and Fig. S1). We found no evidence that α -synuclein became Triton-insoluble under hyper-phosphorylation condition (supported by data in Fig. 2 in Chau et al. 2009 and Fig. S2), justifying the examination of only the Triton-soluble cell lysates in our system.

Figure 1a is a graphical presentation of the data to illustrate the time-dependent and dose-dependent relationship of PPX treatment in decreasing the constitutive P-S129 α -synuclein level. The data have been normalised to the control (represented as 100 %; mean, 100.5 ± 11.2 %). The reduction in P-S129 levels became significant at 48 h for 10 or 100 μM PPX and 100 μM for its dopamine receptor inactive enantiomer SND, with further time-dependent decreases to 72 h for 100 μM PPX. These data indicate that the effect on P-S129 is independent of the dopamine receptors. Further demonstration of PPX acting independently of the dopamine receptors came from the use of the dopamine receptor antagonist clozapine co-incubated with PPX (Fig. S3). Clozapine had no effect on P-S129 α -synuclein. Figure 1b shows the typical Western blot images of the cells treated with a range of PPX concentrations or its enantiomer SND for a period up to 72 h, immunostained with the antibody detecting P-S129 and total levels of α -synuclein and β -actin.

Treatment with the phosphatase inhibitor OKA over 30 min led to an accumulation of P-S129 α -synuclein that allowed measurement of the rate of P-S129 formation and the activity of the kinases responsible for phosphorylation (Chau et al. 2009). Shown in Fig. 1c is a graphical representation of Western blot images (normalised to the control as 100 %; mean, 96.2 ± 5.6 %), and Fig. 1d is a typical image of the cells treated with 100 μM PPX or SND for a period up to 72 h, followed by OKA. Our data demonstrate a time-dependent decrease in the rate of P-S129 α -synuclein formation with PPX or SND treatment, becoming statistically significant at 72 h. In our system, the kinases contributing to P-S129 α -synuclein appear to be inhibited by PPX in a dopamine receptor-independent manner.

Pramipexole Reduced the Proteasome Inhibition-Induced Level and Formation Rate of α -Synuclein Phosphorylation at Serine-129

In view of proteasomal inhibition as a model of PD (Imamura et al. 2008; Li et al. 2010), we studied this effect with epoxomicin on the levels of P-S129. Epoxomicin (at 14 nM for 24 h) significantly induced the constitutive level of P-S129 α -synuclein as well as the rate of its phosphorylation (Fig. 2a–c). Both PPX and its enantiomer SND pre-incubated for 48 h reduced the rate and levels of P-S129, increased upon epoxomicin treatment, in a dose-dependent manner that was significant at 100 μM . These data suggest that the kinases responsible for P-S129 α -synuclein were upregulated by proteasomal inhibition and negatively controlled by PPX independently of its dopamine receptor property.

Influence of PPX on α -Synuclein Phosphorylation at Serine-129 Induced by Proteasome Inhibition Does Not Appear to be Related to Cell Viability and α -Synuclein Oligomerisation

We determined whether PPX prevents cell loss upon epoxomicin treatment. The 24-h treatment with epoxomicin at 14 nM caused no noticeable death of SH-SY5Y cells (data not shown) despite the typical fourfold increase in P-S129 α -synuclein. Epoxomicin treatment at 14 nM for 72 h produced a 49 ± 2 % LDH release, but no protection is seen upon co-incubation with PPX (Fig. S4A) despite the typical reduction of P-S129 α -synuclein. Similar observations were made by Imamura et al. (2008) from using another proteasome inhibitor lactacystin.

We also determined whether increased P-S129 α -synuclein mediated by proteasome inhibition is associated with oligomerisation of α -synuclein in vivo. Following treatment with epoxomicin or bafilomycin (known to cause α -synuclein accumulation and oligomerisation), we

captured all α -synuclein, followed by detecting either the total level of α -synuclein or the α -synuclein oligomers by the A11 antibody using an ELISA approach. Figure S4B shows that, unlike bafilomycin treatment, epoxomicin treatment for 24 h produced a small signal of α -synuclein oligomerisation, and it did not seem to be influenced by PPX co-incubation. Our observation is in contrast to that seen *in vitro* by Kakimura et al. (2001), in which PPX produced an inhibitory effect on α -synuclein aggregation induced by H_2O_2 .

α -Synuclein Phosphorylation at Serine-129 was Dependent on Casein Kinase 2

A number of kinases have been identified to contribute to the formation of P-S129 α -synuclein (Waxman and Giasson 2008; Mbefo et al. 2010; Braithwaite et al. 2012). Previously, we demonstrated that casein kinase 2 (CK2) was responsible for half of the kinase activity phosphorylating α -synuclein at serine-129 in our model (Chau et al. 2009). In this study, a more specific CK2 inhibitor, TBB (used at 10 μ M for 30 min), was found to significantly reduce the constitutive and epoxomicin-induced levels and rates of generation of P-S129 α -synuclein (Fig. 3a–c). These data provide additional support for the predominant position of CK2 as the kinase in both cases of the constitutive and induced P-S129 α -synuclein.




Fig. 1 PPX, in a D2/D3-independent manner, decreased the constitutive level and rate of α -synuclein phosphorylation at serine-129 (P-S129) in SH-SY5Y cells. PPX, and its enantiomer SND, decreased the constitutive level of P-S129 (against the total level of α -synuclein-HA), in a time-dependent and dose-dependent manner (a). Such decrease became significant ($*p < 0.05$, $**p < 0.01$; by ANOVA followed by Dunnett) upon 100 μ M PPX/SND incubation for 48 h or longer. Shown are the mean \pm SEM signals

Fig. 2 PPX-induced D2/D3-independent reduction of the level and rate of α -synuclein phosphorylation at serine-129 (P-S129) by proteasome inhibition in SH-SY5Y cells. Epoxomicin (14 nM for 24 h) significantly (by *t* test) induced the constitutive level (a) and rate (b) of P-S129, whereas PPX or SND (when pre-incubated for 48 h and co-incubated with Epox) decreased the induced level and rate of P-S129, in a dose-dependent manner, reaching significance (by ANOVA followed by Dunnett and by *t* test) at 100 μ M. Shown are the mean \pm SEM signals of P-S129 corrected by HA of six experiments. c A typical Western blot image reflecting data shown in a and b







Pramipexole Decreases the Abundance of P-S209 of Casein Kinase 2- β

As the first step to delineate how PPX controls the kinase responsible for P-S129 α -synuclein, we found that both PPX and the enantiomer (at 100 μ M after 48 h) significantly reduced the phosphorylation of the β -subunits of CK2 at serine-209 (Fig. 4a, b), whereas the endogenous expression of CK2 was unaffected. These data have shed light to the potential influence of PPX to an upstream signal transduction pathway of CK2 in phosphorylating α -synuclein at serine-129.

Pramipexole Does Not Function as an Inhibitor to CK2 *In Vitro*

Next, we asked the question whether PPX (at 10 μ M) functions as a kinase inhibitor *in vitro*. On a panel of 27 candidate

of P-S129 corrected by HA of seven experiments. Typical Western blot results are shown in b. PPX at 100 μ M (c) decreased the rate of P-S129, in a time-dependent manner, which reached significance (by ANOVA) by 72 h incubation. Enantiomer SND at 100 μ M caused a statistically significant reduction after evaluation by *t* test. Shown are the mean \pm SEM signals of P-S129 corrected by HA over a period of 30 min in the presence of 1 μ M OKA of 11 experiments. d A typical Western blot image



kinases examined, from the standard SelectScreen biochemical kinase profiling service (Life Technologies, Paisley, UK), inhibition was $\leq 10\%$, including CK2, glycogen synthase kinase 3 β , Akt that is downstream of phosphatidylinositol 3'-kinase and leucine-rich repeat kinase 2 (Suppl. Table). These data suggest that PPX does not inhibit the activity of

Fig. 3 Inhibition of CK2 decreased the level and rate of α -synuclein phosphorylation at serine-129 (P-S129) in SH-SY5Y cells. Specific CK2 inhibitors DRB and TBB significantly decreased the constitutive level (a) of P-S129 (against the total level of α -synuclein-HA), as well as the rate (b) (by *t* test). Shown are the mean \pm SEM signals of P-S129 corrected by HA of three experiments. c Typical Western blot images




Fig. 4 D2/D3-independent decrease in the level of P-S209 CK2- β by PPX in SH-SY5Y cells. PPX, and its enantiomer SND, decreased the level of P-S209 (against the total level of CK2- β), in a time-dependent and dose-dependent (**a**) manner, significant ($*p < 0.05$; by ANOVA followed by Dunnett) upon 100 μ M PPX/SND incubation for 48 h. Shown are the mean \pm SEM signals of P-S209 corrected by the total level of CK2- β of four experiments. Typical Western blot results are shown in **b**

CK2 and/or the kinases responsible for P-S129 α -synuclein by direct interaction.

Proteasomal Activities Stimulated by Pramipexole

There are some lines of evidence that PPX affects proteasomal activities (Imamura et al. 2008; Li et al. 2010). Measurements using fluorogenic substrates on SH-SY5Y lysates enabled us to estimate proteasomal activities. Although measurements from three different substrates all produced significant reduction in activities upon epoxomicin treatment, the ability to restore the loss of proteasomal activities and to stimulate proteasomal activities by PPX or SND alone are moderate (Fig. S5A–C). We also measured the steady-state level of ubiquitination in our model, which showed a significant increase in the level of ubiquitinated protein upon epoxomicin treatment. Although not significant, PPX treatment reduced the constitutive and epoxomicin-induced level of ubiquitinated protein (Fig. S5D).

Discussion

In a human dopaminergic cell-based system with stable expression of α -synuclein, we have demonstrated that the

dopamine agonist PPX can reduce both the level and rate of phosphorylation of this protein at serine-129. α -Synuclein P-S129 is the predominant form of this protein in Lewy bodies, and this post-translational modification may be important in mediating toxicity (Chau et al. 2009; Kragh et al. 2009). Both proteasomal inhibition and increased free radical generation are considered important in PD pathogenesis (Schapira 2006) and both result in an increase in P-S129 α -synuclein (Chau et al. 2009), although the underlying mechanism is not known. The dopamine receptor inactive PPX enantiomer SND demonstrated similar properties, implying that the effects on α -synuclein phosphorylation are not mediated via dopamine receptor agonist activity. This reduction in α -synuclein phosphorylation was produced through a reduction in the rate of formation of P-S129 modification, suggesting that these compounds could modulate the kinase activity involved. PPX was also effective in decreasing P-S129 formation induced by proteasomal inhibition. As illustrated in Fig. 5, we propose that PPX (in a dopamine receptor-independent fashion) stimulates proteasomal activities preventing kinase-mediated P-S129 formation and promoting turnover of P-S129 (which was shown processed by proteasome; Chau et al. 2009; Machiya et al. 2010).

In vitro experimentation has suggested that CK1 and CK2, G protein-coupled receptor kinase 2 and 5 and polo-like kinase 2 are all capable of phosphorylating α -synuclein at serine-129 (reviewed by Waxman and Giasson 2008; Mbefo et al. 2010; Braithwaite et al. 2012). We confirmed that CK2 inhibitors substantially reduce the phosphorylation of α -synuclein at serine-129, which supports that CK2 contributes, to a certain extent, to this process in our system. Our findings that PPX and its enantiomer in turn influenced




Fig. 5 Schematic diagram outlining the potential influence of PPX for P-S129 α -synuclein in this study. Items in *black* are derived from definite experimental evidence, whereas those in *grey* are descriptive

the phosphorylation of the β -subunits of CK2 at serine-209 (Bodenbach et al. 1994; Litchfield 2003) provide a possible mechanism for how these compounds reduce α -synuclein phosphorylation by modulating the CK2 signalling pathway and the potential protective effect of PPX. However, our limited in vitro kinase profiling indicates that PPX did not inhibit many candidate kinases at 10 μ M level.

In the same cell line used in these experiments and at similar concentrations used here, both PPX and SND have demonstrated protection against the toxins 1-methyl-4-phenylpyridinium, rotenone, paraquat, hydrogen peroxide and lactacystin (Gu et al. 2004; Iravani 2008; Ferrari-Toninelli et al. 2010). It has been proposed that PPX may exert its protective effects through several pathways, including mitochondrial protection, anti-apoptotic, anti-inflammatory and growth factor-like effects (Gu et al. 2004; Presgraves et al. 2004; Du et al. 2005; Izumi et al. 2007; Iravani et al. 2008). A protective effect has also been seen in primates in MPTP toxicity in vivo (Iravani et al. 2006) and in rodents against lipopolysaccharide-induced inflammation (Ferrari-Toninelli et al. 2010) and proteasomal inhibition (Imamura et al. 2008; Li et al. 2010). Our current finding that PPX reduced α -synuclein phosphorylation may provide a mechanistic explanation to the proteasome impairment model. It is worth investigating the neuroprotective effect of PPX in this model. The decrease in P-S129 induced by PPX adds an additional candidate pathway for the protective effects seen.

These results have several interesting implications. A double-blind randomised delayed start study of PPX in early PD has just been completed (Schapira et al. 2010). If the reduction in formation of P-S129 is a significant pathway contributing to protection, it might be expected to have a slow cumulative effect, reflecting the gradual but progressive evolution of the disease (Braak et al. 2003). The action on P-S129 does not seem to be dependent upon the activation of the dopamine receptor and so it is possible that any protection might be seen in dopaminergic and non-dopaminergic pathways, i.e. any neuron in which Lewy bodies form. This is important, as a significant component of PD morbidity is determined by non-dopaminergic degeneration. Finally, the phosphorylation pathway of α -synuclein may represent a valid target for drug discovery in PD in terms of developing additional compounds for investigation as protective agents.

Acknowledgements The authors' work described here was supported in part by an unrestricted grant from Boehringer Ingelheim, the Wellcome Trust/Medical Research Council (MRC) Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium, whose members are from the University College London/Institute of Neurology, University of Sheffield, and MRC Protein Phosphorylation Unit at the University of Dundee. We also acknowledge the support of Parkinson's UK, the Kattan Trust and MRC/COEN007/MR/J009660/1.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

- Anderson JP et al (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. *J Biol Chem* 281:29739–29752
- Bodenbach L et al (1994) Recombinant human casein kinase II. A study with the complete set of subunits (alpha, alpha' and beta), site-directed autophosphorylation mutants and a bicistronically expressed holoenzyme. *Eur J Biochem* 220:263–273
- Braak H et al (2003) Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 24:197–211
- Braithwaite SP et al (2012) α -Synuclein phosphorylation as a therapeutic target in Parkinson's disease. *Rev Neurosci* 23:191–198
- Chau KY et al (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. *J Neurochem* 110:1005–1013
- Chaudhuri KR et al (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. *Lancet Neurol* 5:235–245
- Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. *Lancet Neurol* 8:464–474
- Dagda RK, Zhu J, Chu CT (2009) Mitochondrial kinases in Parkinson's disease: converging insights from neurotoxin and genetic models. *Mitochondrion* 9:289–298
- Devi L, Anandatheerthavarada HK (2010) Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. *Biochim Biophys Acta* 1802:11–19
- Du F, Li R, Huang Y, Li X, Le W (2005) Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. *Eur J Neurosci* 22:2422–2430
- Ferrari-Toninelli G et al (2010) Mitochondria-targeted antioxidant effects of S(-) and R(+) pramipexole. *BMC Pharmacol* 10:2
- Fox SH et al (2008) Non-dopaminergic treatments in development for Parkinson's disease. *Lancet Neurol* 7:927–938
- Fuchs J et al (2008) Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. *FASEB J* 22:1327–1334
- Fujiwara H et al (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. *Nat Cell Biol* 4:160–164
- Gu M et al (2004) Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. *J Neurochem* 91:1075–1081
- Imamura K et al (2008) Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity. *Neurosci Lett* 440:97–102
- Iravani MM et al (2006) Pramipexole protects against MPTP toxicity in non-human primates. *J Neurochem* 96:1315–1321
- Iravani MM et al (2008) Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response. *Exp Neurol* 212:522–531
- Izumi Y et al (2007) Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. *Eur J Pharmacol* 557:132–140
- Kakimura J et al (2001) Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. *Eur J Pharmacol* 417:59–67

- Kragh CL et al (2009) α -Synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. *J Biol Chem* 284:10211–10222
- Li C et al (2010) Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease. *Neurochem Res* 35:1546–1556
- Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. *Biochem J* 369:1–15
- Machiya Y et al (2010) Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. *J Biol Chem* 285:40732–40744
- Mbefo MK et al (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. *J Biol Chem* 285:2807–2822
- Nakamura K et al (2011) Direct membrane association drives mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. *J Biol Chem* 286:20710–20726
- Obeso JA et al (2010) Missing pieces in the Parkinson's disease puzzle. *Nat Med* 16:653–661
- Olanow CW et al (2008) Why have we failed to achieve neuroprotection in Parkinson's disease? *Ann Neurol* 64(Suppl 2):S101–S110
- Presgraves SP et al (2004) Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells. *Exp Neurol* 190:157–170
- Ross OA et al (2008) Genomic investigation of alpha-synuclein multiplication and parkinsonism. *Ann Neurol* 63:743–750
- Schapira AH (2006) Etiology of Parkinson's disease. *Neurology* 66:S10–S23
- Schapira AH (2008) Progress in neuroprotection in Parkinson's disease. *Eur J Neurol* 15(Suppl 1):5–13
- Schapira AH (2009a) Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease. *Neurology* 72:S44–S50
- Schapira AH (2009b) Neurobiology and treatment of Parkinson's disease. *Trends Pharmacol Sci* 30:41–47
- Schapira AH et al (2009) Perspectives on recent advances in the understanding and treatment of Parkinson's disease. *Eur J Neurol* 16:1090–1099
- Schapira AH et al (2010) Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. *Mov Disord* 25:1627–1632
- Schapira AH, Tolosa E (2010) Molecular and clinical prodrome of Parkinson disease: implications for treatment. *Nat Rev Neurol* 6:309–317
- Sha D et al (2010) Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. *Hum Mol Genet* 19:352–363
- Wakamatsu M et al (2007) Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. *J Neurosci Res* 85:1819–1825
- Waxman EA, Giasson BI (2008) Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein. *J Neuropathol Exp Neurol* 67:402–416